The ORAL surveillance study found the serum lipid levels (fasting triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol and total cholesterol) were higher in RA patients treated with Tofacitinib than in those treated with the TNF inhibitor, which might be associated with an increased risk of VTE (HR = 3.52, 95% CI: 1.74–7.12) and a trend towards an increased risk of MACE (HR = 1.43, 95% CI: 0.94–2.18) found in patients treated with the JAKinib [9]. The gene discussed is TNF; the disease is rheumatoid arthritis.